^
BIOMARKER:

RET mutation

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Entrez ID:
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: A2 - Guideline
RET mutation
Thyroid Gland Medullary Carcinoma
TPX 0046
Sensitive: C2 – Inclusion Criteria
RET mutation
NSCLC
TPX 0046
Sensitive: C2 – Inclusion Criteria
RET mutation
NSCLC
BOS-172738
Sensitive: C2 – Inclusion Criteria
RET mutation
Thyroid Gland Medullary Carcinoma
BOS-172738
Sensitive: C2 – Inclusion Criteria
RET mutation
Thyroid Gland Medullary Carcinoma
RET inhibitor
Sensitive: C3 – Early Trials
RET mutation
Thyroid Gland Carcinoma
LDD-2633
Sensitive: D – Preclinical
RET mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
RET mutation
Thyroid Gland Carcinoma
CB-228 + AST-487
Sensitive: D – Preclinical
RET mutation
Thyroid Gland Carcinoma
AST-487
Sensitive: D – Preclinical